Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Der f 33 is **alpha-tubulin**, a protein allergen derived from the American house dust mite (*Dermatophagoides farinae*). It has a molecular weight of approximately 52 kDa and is classified as a novel allergen within the spectrum of house dust mite allergens. Der f 33 has demonstrated allergenicity in human testing: four out of sixteen house dust mite–allergic serum samples reacted positively in skin prick tests, and strong IgE binding was observed in immunoblot and IgE western blot experiments. The route of exposure is via inhalation, leading to sensitization in susceptible individuals, particularly those with house dust mite allergies. The protein's alpha-tubulin function relates to its structural role in the microtubule system, but its clinical relevance is due to its ability to trigger IgE-mediated allergic responses[3][1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Der f 33.